Mubadala Capital

← Back to your selection

Activity in this selectionfine-structure-ventures-993662cc

Rounds participated in: 3
Confirmed lead rounds: —
New companies: 3
Funding in participating rounds: $403.5M

By stage

Series B2

Series C+1

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection

Jun 24

Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Apr 15

Alloy Therapeutics

Provides AI-powered platforms and integrated services for drug discovery and development

$40MSeries E

Role not disclosed

Jan 12

Juvena Therapeutics

Develops regenerative biologics to restore tissue function

$33.5MSeries B

Role not disclosed

← Back to your selection

Activity in this selectionfine-structure-ventures-993662cc

Rounds participated in: 3
Confirmed lead rounds: —
New companies: 3
Funding in participating rounds: $403.5M

By stage

Series B2

Series C+1

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection

Jun 24

Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Apr 15

Alloy Therapeutics

Provides AI-powered platforms and integrated services for drug discovery and development

$40MSeries E

Role not disclosed

Jan 12

Juvena Therapeutics

Develops regenerative biologics to restore tissue function

$33.5MSeries B

Role not disclosed